Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) have received an average recommendation of “Buy” from the seven research firms that are covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $33.86.
A number of research analysts have recently issued reports on EYPT shares. JPMorgan Chase & Co. started coverage on EyePoint Pharmaceuticals in a report on Monday, January 22nd. They issued an “overweight” rating and a $35.00 price target on the stock. Mizuho raised their price objective on EyePoint Pharmaceuticals from $30.00 to $39.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. HC Wainwright lowered their price objective on EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, January 16th. Finally, Capital One Financial reissued an “overweight” rating on shares of EyePoint Pharmaceuticals in a research report on Friday, February 16th.
Read Our Latest Report on EyePoint Pharmaceuticals
Insider Activity
Hedge Funds Weigh In On EyePoint Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of EYPT. JPMorgan Chase & Co. increased its stake in shares of EyePoint Pharmaceuticals by 41.1% in the 1st quarter. JPMorgan Chase & Co. now owns 15,730 shares of the company’s stock valued at $191,000 after purchasing an additional 4,578 shares in the last quarter. Bank of New York Mellon Corp increased its stake in EyePoint Pharmaceuticals by 5.3% during the 1st quarter. Bank of New York Mellon Corp now owns 79,407 shares of the company’s stock worth $966,000 after buying an additional 3,985 shares in the last quarter. MetLife Investment Management LLC increased its stake in EyePoint Pharmaceuticals by 55.5% during the 1st quarter. MetLife Investment Management LLC now owns 12,835 shares of the company’s stock worth $156,000 after buying an additional 4,582 shares in the last quarter. Rhumbline Advisers increased its stake in EyePoint Pharmaceuticals by 33.8% during the 1st quarter. Rhumbline Advisers now owns 29,463 shares of the company’s stock worth $358,000 after buying an additional 7,438 shares in the last quarter. Finally, BlackRock Inc. increased its stake in EyePoint Pharmaceuticals by 5.9% during the 1st quarter. BlackRock Inc. now owns 1,526,153 shares of the company’s stock worth $18,543,000 after buying an additional 85,522 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.
EyePoint Pharmaceuticals Stock Up 2.6 %
EYPT opened at $21.84 on Friday. The stock’s fifty day moving average is $24.31 and its two-hundred day moving average is $18.25. The company has a market capitalization of $1.09 billion, a P/E ratio of -11.93 and a beta of 1.64. EyePoint Pharmaceuticals has a 52 week low of $4.22 and a 52 week high of $30.99.
EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.27. The company had revenue of $14.03 million for the quarter, compared to the consensus estimate of $8.71 million. EyePoint Pharmaceuticals had a negative return on equity of 61.48% and a negative net margin of 153.84%. During the same period last year, the business posted ($0.61) EPS. Equities analysts anticipate that EyePoint Pharmaceuticals will post -1.73 earnings per share for the current year.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Further Reading
- Five stocks we like better than EyePoint Pharmaceuticals
- Roth IRA Calculator: Calculate Your Potential Returns
- Silicon Motion Proves That AI in Motion Stays in Motion
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Undervalued UnitedHealth Group Won’t Be For Long
- Stock Dividend Cuts Happen Are You Ready?
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.